Table 3 Comparison between group 2 (pts received mRNA-based vaccines with adverse events) vs group 3 (pts received inactivated virus-based vaccines with adverse events)
Group 2 (mRNA vaccines) | Percentage | Group 3 (inactivated virus vaccine) | Percentage | DIFF/95 CI/chi-squared/DF/significance | |
|---|---|---|---|---|---|
Thrombosis/thrombocytopenia | 1 | 0.20% | 0 | 0% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
ICH | 0 | 0 | 0 | 0% | 0%/− 0.8282–0.8282% |
DIC | 0 | 0 | 0 | 0% | 0%/− 0.8282–0.8282% |
GBS | 5 | 1% | 0 | 0% | 1%/− 0.0148–2.3981%/4.618/1/P = 0.0316 |
Acute TM | 1 | 0.20% | 1 | 0.20% | 0%/− 1.0055–1.0055%/0/1/P = 1.0000 |
Acute demyelinating polyradiculopathy | 0 | 0 | 0 | 0% | 0%/− 0.8282–0.8282% |
Acute disseminated encephalomyelitis | 1 | 0.20% | 0 | 0% | .2%/− 0.6448-1.1916%/0.920/1/P = 0.3375 |
Inflammatory myositis | 0 | 0 | 0 | 0% | 0%/− 0.8282–0.8282% |
Erythema nodosum | 0 | 0 | 0 | 0% | 0%/− 0.8282–0.8282% |
Renal complication | 36 | 8% | 1 | 0.20% | 7.8%/5.4365–10.6460%/35.550/1/P < 0.0001 |
Acute macular neuroretinopathy/ facial palsy/ choroiditis | 66 | 14% | 1 | 0.20% | 13.8%/10.7601–17.2739%/66.335/1/P < 0.0001 |
Cutaneous vasculitis | 1 | 0.20% | 0 | 0% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Myocarditis | 22 | 5% | 0 | 0% | 5%/3.1579%/7.3908%/23.564/1/P < 0.0001 |
Acute myocardial infarction | 2 | 0.40% | 0 | 0% | .4%/− 0.4793–1.5170%/1.842/1/P = 0.1748 |
ITP | 4 | 0.80% | 0 | 0% | .8%/− 0.1674–2.1148%/3.691/1/P = 0.0547 |
Miller Fisher S | 1 | 0.20% | 0 | 0% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Sarcoid reaction | 1 | 0.20% | 0 | 0% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Steven Johnson Syndrome | 1 | 0.20% | 0 | 0% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
Uveitis | 0 | 0.00% | 1 | 0.20% | .2%/− 0.6448–1.1916%/0.920/1/P = 0.3375 |
142 | 31% | 4 | 0.80% | 30.2%/25.9377–34.5977%/156.703/1/P < 0.0001 |